BRAF/MEK Combo Approved for Melanoma
Encorafenib/binimetinib an option for patients with metastatic or inoperable disease with BRAF mutation.
CDK12 Alterations Telling for Some with Prostate Cancer
Patients with inactivating mutations in that gene may be more likely to respond to checkpoint inhibitor.
Study Reveals Hereditary Basis of Pancreatic Cancer
Germline mutations in six disease-associated genes were found in 5.5% of patients, supporting broader genetic testing.
Quizartinib Bests Chemo for FLT3-Mutant AML
Targeted agent extends survival for patients with relapsed or refractory disease.
Positive Results for Tazemetostat in Follicular Lymphoma
Phase II study finds drug effective in patients with EZH2 mutations.
Pembrolizumab OK'd for Cervical Cancer
PD-1 inhibitor becomes the first approved for a gynecologic cancer.
Roche to Buy Balance of Foundation Medicine
With $2.4 billion deal, Swiss drug giant tightens ties to genetic-testing firm.
Abiraterone–Olaparib Combo Aids Men with mCRPC
HRR deficiency isn't factor in therapeutic response to antiandrogen and PARP inhibitor in metastatic castrate-resistant prostate cancer.
Trastuzumab Deruxtecan Targets HER2+ Cancers
Antibody–drug conjugate generates many responses, shrinks high percentage of tumors in phase I trial.
Erdafitinib Efficacious in Bladder Cancer
FGFR inhibitor yields robust responses, even in those who did not respond to immunotherapy.
Study Reveals Germline Genetics of Medulloblastoma
Researchers identify six mutations that account for 6% of cases, a finding that could improve treatment.
Ivosidenib Deemed Safe, Effective in AML
Study suggests that IDH1 inhibitor induces remission in patients with relapsed or refractory disease.
Antibiotics Protect Against Liver Tumors in Mice
An altered gut microbiome leads to the accumulation of hepatic natural killer T cells.
An Immunosuppressive Role for Eya3 in TNBC
Protein suppresses CD8+ T cells, upregulates PD-L1 to drive their exhaustion and spur tumor growth.
Squamous NSCLC Improves with Atezolizumab Plus Chemo
Patients treated with drug combination had longer PFS and higher ORR than those who received chemotherapy alone.
President Signs STAR Act for Kids' Cancers
Legislation aims to expand collection of biospecimens, improve surveillance, and support research on survivorship.
Maintenance Chemo Improves Pediatric RMS
Following standard therapy, low-dose cyclophosphamide plus vinorelbine extends rhabdomyosarcoma survival.
Genome Sequencing Detects Lung Cancer in Blood
Three different assays use cell-free DNA to find the disease with high specificity, sensitivity.
Pembrolizumab Monotherapy for NSCLC Extends Survival
The PD-1 inhibitor improves OS in patients with advanced disease and PD-L1 expression of 1% or higher.
Lynch Syndrome Linked with More Cancers
Hereditary condition common among patients with MSI-high tumor types besides colorectal, endometrial cancers.